Stocks Health care JBIO
NASDAQ · Health careJade Biosciences, Inc. (JBIO)
It posted a net loss of $153.2M. In fiscal 2025 capital spending exceeded operating cash flow by $94.9M. At June 30, 2026 it held $107.3M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 10, 2026.
Key facts about Jade Biosciences, Inc.
- Net worth
- Jade Biosciences, Inc. has a market value (market cap) of $1B at the latest share price, and shareholders' equity of $439.9M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2025 operations used $94.7M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 10, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Jade Biosciences, Inc.'s next report is expected around November 13, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What Jade Biosciences, Inc. does
Jade Biosciences, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker JBIO.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$127.4M | -$3.19 | -$94.9M |
| 2024 | n/a | -$69.6M | -$2.44 | n/a |
| 2023 | n/a | -$75.5M | -$2.87 | -$56.9M |
| 2022 | n/a | -$51.5M | -$2.10 | -$39.3M |
| 2021 | n/a | -$23M | -$1.87 | -$27.6M |
| 2021 | n/a | -$9.6M | -$40.31 | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Jade Biosciences, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 27, 2026Passive stake (5% or more) SCHEDULE 13G
- September 30, 2026Other event 8-K
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 10, 2026
- August 10, 2026
- July 17, 2026Passive stake (5% or more) SCHEDULE 13G
- July 8, 2026Passive stake changed SCHEDULE 13G/A
- July 1, 2026
- June 26, 2026
Insider trades
What the people running Jade Biosciences, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| February 12, 2026 | King Andrew JamesSee Remarks | Received as pay | 41,250 | - |
| February 12, 2026 | Frohlich TomChief Executive Officer, Director | Received as pay | 78,750 | - |
| February 12, 2026 | Balta ElizabethSee Remarks | Received as pay | 28,125 | - |
| February 12, 2026 | Dahms Bradford D.Chief Financial Officer | Received as pay | 37,813 | - |
Who owns JBIO
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Fairmount Funds Management LLC13D, may seek influence with 4 related filers | 19.99% | June 9, 2026 |
| Fmr LLC13G, passive with 1 related filers | 14.7% | June 6, 2025 |
| JANUS HENDERSON GROUP Ltd.13G, passive | 10.6% | July 8, 2026 |
| Venrock Healthcare Capital Partners III, L.P.13G, passive with 6 related filers | 8.3% | August 14, 2026 |
| RA Capital Management, L.P.13G, passive with 3 related filers | 7% | October 16, 2025 |
| BlackRock, Inc.13G, passive | 5.2% | October 27, 2026 |
| Paradigm BioCapital Advisors LP13G, passive with 3 related filers | 5.1% | July 17, 2026 |
| Bellevue Group AG13G, passive with 1 related filers | 5% | August 14, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 154 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Fmr LLC | 9,126,877 | +2,041,454 |
| Jupiter Topco LLC | 6,273,262 | new |
| Fairmount Funds Management LLC | 4,553,494 | 0 |
| RA Capital Management, L.P. | 3,671,083 | 0 |
| Venrock Adviser, LLC | 3,220,364 | 0 |
| Bellevue Group AG | 3,057,996 | -443,506 |
| Paradigm Biocapital Advisors LP | 2,857,405 | new |
| BlackRock, Inc. | 2,801,451 | +487,502 |
| Franklin Resources Inc | 2,792,080 | new |
| State Street Corp | 2,335,285 | +1,679,595 |
| Vanguard Capital Management LLC | 2,244,773 | +448,121 |
| Adage Capital Partners GP, L.L.C. | 1,910,812 | new |
| Polar Capital Holdings Plc | 1,846,982 | new |
| Avidity Partners Management LP | 1,700,708 | -1,100,708 |
| Remedium Capital Partners, LLC | 1,577,750 | 0 |
| Soleus Capital Management, L.P. | 1,550,690 | +753,946 |
| Jpmorgan Chase & Co | 1,475,079 | +1,459,216 |
| Baker Bros. Advisors LP | 1,230,426 | -410,711 |
| Logos Global Management LP | 1,125,000 | +725,000 |
| Versant Venture Management, LLC | 991,783 | -534,037 |
Insiders
4 insiders reported holding 538,382 shares in total, about $8.8M at the last price.
| Holder | Shares |
|---|---|
| King Andrew JamesSee Remarks | 386,113 |
| Frohlich TomChief Executive Officer, Director | 86,331 |
| Dahms Bradford D.Chief Financial Officer | 37,813 |
| Balta ElizabethSee Remarks | 28,125 |
Questions about JBIO
What does Jade Biosciences, Inc. do?
Jade Biosciences, Inc. is a company in the Health care sector, listed on NASDAQ as JBIO. Its shares trade on NASDAQ under the ticker JBIO.
What is Jade Biosciences, Inc.'s net worth?
Jade Biosciences, Inc. has a market value (market cap) of $1B at the latest share price, and shareholders' equity of $439.9M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Jade Biosciences, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $153.2M.
When did Jade Biosciences, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 10, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the passive stake (5% or more) from October 27, 2026.
When is Jade Biosciences, Inc.'s next earnings report?
Jade Biosciences, Inc.'s next report is expected around November 13, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare JBIO with
Follow JBIO
Get an email when Jade Biosciences, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Jade Biosciences, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.